TGFB1 anticorps (AA 279-390)

N° du produit ABIN2903529

L’anticorps Lapin Polyclonal anti-TGFB1 a été validé pour WB, IHC, IP et IF/ICC. Il convient pour détecter TGFB1 dans des échantillons de Souris.

Aperçu rapide pour TGFB1 anticorps (AA 279-390) (ABIN2903529)

Antigène: TGFB1 (Transforming Growth Factor, beta 1 (TGFB1))

Reactivité: Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp TGFB1 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunoprecipitation (IP), Immunofluorescence (fixed cells) (IF/ICC)

Détail du produit anti-TGFB1 anticorps

Épitope: AA 279-390

Purification: Antigen-specific affinity chromatography followed by Protein A affinity chromatography

Immunogène: TGFb1 (Ala279-Ser390)

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 500 μg/mL

Buffer: 0.01M PBS,  pH 7.4, containing 0.05 % Proclin-300, 50 % glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at 4 °C for frequent use. Aliquot and store at -20 °C for one year. Avoid repeated freeze/thaw cycles.

Détails sur TGFB1

Antigène: TGFB1 (Transforming Growth Factor, beta 1 (TGFB1))

Autre désignation: Transforming Growth Factor beta 1

UniProt: P04202

Pathways: EGFR Signaling Pathway, Dopaminergic Neurogenesis, Cellular Response to Molecule of Bacterial Origin, Glycosaminoglycan Metabolic Process, Regulation of Leukocyte Mediated Immunity, Regulation of Muscle Cell Differentiation, Positive Regulation of Immune Effector Process, Cell-Cell Junction Organization, Production of Molecular Mediator of Immune Response, Ribonucleoside Biosynthetic Process, Skeletal Muscle Fiber Development, Regulation of Carbohydrate Metabolic Process, Protein targeting to Nucleus, Autophagy, Cancer Immune Checkpoints